Atlas Trials

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Clinical trial NCT02695290 · TERMINATED

Trial details

NCT number
NCT02695290
Sponsor
Boehringer Ingelheim
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell LungErbB Receptors
Start date
2016-03-17
Primary completion
2016-08-26
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.